Canada [Feature Product: Apo-Atorvastatin
An unprecedented victory
Apotex succeeds in what no other generic company in Canada could do, break through patent '546.
This landmark victory has delivered:
- A generic alternative to Lipitor® 12 years before patent expiry.
- An additional $1.2 billion in annual brand sales to the generic industry. More than twice the value of any generic blockbuster launch to date.
- Over $7 billion in savings to the Canadian healthcare system.
- A Canadian success story – from research and development through to manufacturing, Apo-Atorvastatin is proudly Canadian.
in advancing generics
From the beginning, our single-minded goal has been to provide patients with affordable, high-quality generic pharmaceutical products. And over the years we have consistently delivered on that promise.
We are proud to lead the charge and take on enormous legal challenges and risks, to bring high-quality generics to the Canadian market sooner. In fact, since 1978 Apotex has amassed over 950 registered Federal court cases, appeals and decisions – more than all other major generic competitors combined.
In the past ten years alone we've spent over $800 million in litigation and our legal efforts brought important products like Atorvastatin, Omeprazole, Ramipril and Pantoprazole, among others, to the generic industry, several years before patent expiry.
These recent victories added over $2.7 billion in annual brand sales to the generic market and over $14 billion in savings to the Canadian healthcare system.
Our past victories are a testament to our unwavering commitment to advancing generics in Canada, and a sign of what lies ahead, as we continue to lead the way.
